Abstract
Xipayi Kui Jie’an (KJA), a type of traditional Uygur medicine (TUM), has shown promising therapeutic effects in Ulcerative colitis (UC). Owing to the complexity of TUM, the pharmacological mechanism of KJA remains vague. Therefore, the identification of complex molecular mechanisms is a major challenge and a new method is urgently needed to address this problem. In this study, we established a feasible pharmacological model based on systems pharmacology to identify potential compounds and targets. We also applied compound-target and target-diseases network analysis to evaluate the action mechanisms. According to the predicted results, 12 active compounds were selected and these compounds were also identified by HPLC-ESI-MS/MS analysis. The main components were tannins, this result is consistent with the prediction. The active compounds interacted with 22 targets. Two targets including PTGS2 and PPARG were demonstrated to be the main targets associated with UC. Systematic analysis of the constructed networks revealed that these targets were mainly involved in NF-κB signaling pathway. Furthermore, KJA could also regulate the CD4 + CD25 + Foxp3 + Treg cells. In conclusion, this systems pharmacology-based approach not only explained that KJA could alleviate the UC by regulating its candidate targets, but also gave new insights into the potential novel therapeutic strategies for UC.
Highlights
Xipayi Kui Jie’an (KJA), a type of traditional Uygur medicine (TUM), has shown promising therapeutic effects in Ulcerative colitis (UC)
According to the pathway that we found, Turkish galls mitigate the severity of colitis by activating the expression of peroxisome proliferator-activated receptor (PPAR)-γ, attenuating nuclear factor κB (NF-κB) activation and inhibiting the expression of pro-inflammatory cytokines and COX-2
The compounds of Turkish galls ethyl acetate fraction were identified by HPLC-electrospray ionisation (ESI)-MS/MS profiling analysis
Summary
Xipayi Kui Jie’an (KJA), a type of traditional Uygur medicine (TUM), has shown promising therapeutic effects in Ulcerative colitis (UC). KJA could regulate the CD4 + CD25 + Foxp3 + Treg cells This systems pharmacology-based approach explained that KJA could alleviate the UC by regulating its candidate targets, and gave new insights into the potential novel therapeutic strategies for UC. Some traditional TUM drugs have shown promising therapeutic effects for the treatment of UC5. Xipayi Kui Jie’an (KJA) is a prescribed medicine within the TUM approach. It is known as the “Xipayi gingiva protective solution” in the 1998 edition of the Ministry of Health of the People’s Republic of China Pharmaceutical Standards – Uyghur Medicine[6]. The obtained targets were mapped onto relevant databases to find out their corresponding pathways. following experiments were conducted in order to confirm whether the presumptive results of systemic pharmacology are correct[11,12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
